Drug news
NICE recommends Betmiga (Astellas) for patients with Overactive Bladder
The National Institute for Health and Care Excellence ( NICE) in England and Wales has issued final draft guidance recommending Betmiga (mirabegron) from Astellas for reimbursement. The decision follows a provisional recommendation from the institute in March 2013. Betmiga is recommended for overactive bladder syndrome in people unsuited to antimuscarinic drugs because they are contraindicated, clinically ineffective or cause unacceptable side-effects.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins